Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 1
2014 2
2015 2
2016 3
2017 3
2018 2
2019 6
2020 2
2021 9
2022 8
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Epigenetic upregulation of Schlafen11 renders 
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
Nakata S, Murai J, Okada M, Takahashi H, Findlay TH, Malebranche K, Parthasarathy A, Miyashita S, Gabdulkhaev R, Benkimoun I, Druillennec S, Chabi S, Hawkins E, Miyahara H, Tateishi K, Yamashita S, Yamada S, Saito T, On J, Watanabe J, Tsukamoto Y, Yoshimura J, Oishi M, Nakano T, Imamura M, Imai C, Yamamoto T, Takeshima H, Sasaki AT, Rodriguez FJ, Nobusawa S, Varlet P, Pouponnot C, Osuka S, Pommier Y, Kakita A, Fujii Y, Raabe EH, Eberhart CG, Natsumeda M. Nakata S, et al. Among authors: tsukamoto y. Neuro Oncol. 2023 May 4;25(5):899-912. doi: 10.1093/neuonc/noac243. Neuro Oncol. 2023. PMID: 36273330 Free PMC article.
Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study.
Yamasaki F, Fudaba H, Asano K, Sasayama T, Natsumeda M, Shimabukuro T, Taguchi K, Koizumi S, Nakayama N, Fujii K, Nishibuchi I, Sugiyama K, Yoshida K, Yonezawa U, Yasutomo M, Kawasaki Y, Kakuta K, Katayama K, Tanaka K, Nagashima H, Tsukamoto Y, Ideguchi M, Nishizaki T, Kurozumi K, Hosoya T, Akita T, Kambe A. Yamasaki F, et al. Among authors: tsukamoto y. BMJ Open. 2023 Apr 24;13(4):e071350. doi: 10.1136/bmjopen-2022-071350. BMJ Open. 2023. PMID: 37094899 Free PMC article.
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Abe H, Natsumeda M, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Yoshimura J, Oishi M, Fujii Y. Abe H, et al. Among authors: tsukamoto y. Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):290-295. doi: 10.2176/nmc.ra.2018-0044. Epub 2018 May 31. Neurol Med Chir (Tokyo). 2018. PMID: 29848907 Free PMC article. Review.
GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma.
Natsumeda M, Miyahara H, Yoshimura J, Nakata S, Nozawa T, Ito J, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Oishi M, Hirato J, Wataya T, Ahsan S, Tateishi K, Yamamoto T, Rodriguez FJ, Takahashi H, Hovestadt V, Suva ML, Taylor MD, Eberhart CG, Fujii Y, Kakita A. Natsumeda M, et al. Among authors: tsukamoto y. J Neuropathol Exp Neurol. 2021 Jan 20;80(2):129-136. doi: 10.1093/jnen/nlaa141. J Neuropathol Exp Neurol. 2021. PMID: 33249504
Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features.
Natsumeda M, Chang M, Gabdulkhaev R, Takahashi H, Tsukamoto Y, Kanemaru Y, Okada M, Oishi M, Okamoto K, Rodriguez FJ, Kakita A, Fujii Y, Schreck KC. Natsumeda M, et al. Among authors: tsukamoto y. Brain Tumor Pathol. 2021 Jul;38(3):228-233. doi: 10.1007/s10014-021-00407-0. Epub 2021 Jul 3. Brain Tumor Pathol. 2021. PMID: 34216310
Late relapse of primary central nervous system lymphoma.
Yamanaka R, Morii K, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tsukamoto Y, Ogura R, Natsumeda M, Aoki H, Akiyama K, Saitoh T, Tamura T, Hondoh H, Kawaguchi A, Takahashi H, Fujii Y. Yamanaka R, et al. Among authors: tsukamoto y. Leuk Lymphoma. 2017 Feb;58(2):475-477. doi: 10.1080/10428194.2016.1201570. Epub 2016 Jul 10. Leuk Lymphoma. 2017. PMID: 27397141 No abstract available.
Long-term survivors of primary central nervous system lymphoma.
Yamanaka R, Morii K, Sano M, Homma J, Yajima N, Tsukamoto Y, Ogura R, Natsumeda M, Aoki H, Akiyama K, Saitoh T, Hondoh H, Kawaguchi A, Takahashi H, Fujii Y. Yamanaka R, et al. Among authors: tsukamoto y. Jpn J Clin Oncol. 2017 Feb 23;47(2):101-107. doi: 10.1093/jjco/hyw171. Jpn J Clin Oncol. 2017. PMID: 28175331
Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients.
Takahashi H, Natsumeda M, On J, Watanabe J, Tada M, Shimizu H, Tsukamoto Y, Okada M, Oishi M, Takizawa J, Hayashi Y, Masaki Y, Kakita A, Fujii Y. Takahashi H, et al. Among authors: tsukamoto y. Leuk Lymphoma. 2023 Jun;64(6):1219-1222. doi: 10.1080/10428194.2023.2199895. Epub 2023 Apr 18. Leuk Lymphoma. 2023. PMID: 37070573 No abstract available.
48 results